Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.
There is now good reason to believe that blockade of the adenosine A2A receptor could be of value in the treatment of Parkinson's disease. Peter J. Richardson, Hiroshi Kase and Peter G. Jenner review the actions of this receptor in the striatum, emphasizing its ability to modulate the neuronal activity of striatal GABA-releasing output neurones, and showing that recently developed A2A receptor antagonists are capable of reducing the disabling effects of nigral cell degeneration in primates. They conclude that such antagonists may be useful as novel therapeutic agents for the treatment of Parkinson's disease.
Richardson
P J
PJ
Pharmaceutical Development Centre, Kyowa Hakko Kogyo, Tokyo, Japan.
Kase
H
H
Jenner
P G
PG
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D006801:Humans; D017072:Neostriatum / Q000187:drug effects / Q000503:physiopathology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D058915:Purinergic P1 Receptor Antagonists
D000978:Antiparkinson Agents; D058915:Purinergic P1 Receptor Antagonists